To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

NCT04675931 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

254

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Malaria

Interventions

DRUG: Cipargamin
DRUG: IV Artesunate
DRUG: Coartem

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]
[object Object]